文献速递特殊人群用药药物相互作用治疗药物监测与药物基因组学

洛匹那韦/利托那韦在HIV/HBV合并感染孕妇中的母胎群体药代动力学模型开发

Maternal-Fetal Physiologically Based Population Pharmacokinetics Model Development of Lopinavir/Ritonavir in HIV/HBV Co-infected Pregnant Women to Quantitatively Describe the Gestational PK Characteristics and Predict the Potential Disease-Drug-Drug Interaction (DDDI).
PubMed 文献 · Clin Pharmacokinet · 2025-05-05

本研究基于35例HIV/HBV合并感染孕妇,采用非房室分析和群体药代动力学方法构建洛匹那韦母胎PBPK模型,模拟不同剂量方案及潜在药物相互作用。结果显示标准剂量400/100 mg每12小时可能无法达到有效治疗浓度,与利福平合用时需增加剂量或缩短给药间隔。

要点

  • HIV/HBV合并感染孕妇中洛匹那韦标准剂量可能不足,需评估剂量优化。
  • 与利福平合用时,洛匹那韦需增加剂量或缩短给药间隔。
  • 母胎PBPK模型可定量评估经胎盘转运及疾病-药物-药物相互作用风险。

核心结论

  • 群体PBPK模型成功定量评估洛匹那韦母胎药代动力学,并为HIV/HBV合并感染孕妇的DDI风险评估和剂量优化提供新策略。

研究设计与样本

  • 基于35例HIV/HBV合并感染孕妇的非房室分析和群体药代动力学分析,构建纳入经胎盘转运及疾病/妊娠生理变化的母胎PBPK模型。

主要发现

  • 合并感染孕妇孕中期和孕晚期洛匹那韦AUClast分别为34.1和31.0 mg/L/h。
  • PBPK模拟参数为观察值的0.75至约1.16倍。
  • 孕晚期模拟脐静脉:母体血浆比值约0.16,与PopPK模拟个体值0.116一致。
  • 模拟显示标准剂量LPV/r(400/100 mg Q12h)可能无法达到有效治疗浓度。
  • 与利福平合用时模拟提示需增加洛匹那韦剂量或缩短给药间隔。

临床怎么用

  • 临床应关注HIV/HBV合并感染孕妇使用标准剂量LPV/r时可能暴露不足,考虑治疗药物监测。
  • 与利福平联用时应调整洛匹那韦剂量或给药间隔,并密切监测疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Lopinavir/ritonavir (LPV/r) has been widely used in HIV/HBV co-infected pregnant-women. We aim to characterize the maternal-fetal (m-f) pharmacokinetic (PK) of LPV/r and support the dose optimization and potential drug-drug interaction (DDI) evaluation in this population. METHODS: Lopinavir PK characteristics in human immunodeficiency virus/hepatitis B virus (HIV/HBV) co-infected pregnant women (n = 35) and fetus were calculated using non-compartmental analysis followed by quantification of maternal PK characteristics using population PK (PopPK) analysis. A maternal-fetal lopinavir physiologically based pharmacokinetic (PBPK) model was developed by incorporating trans-placental transfer, disease- and pregnancy-related physiological changes. This final population PBPK model was applied to simulate different dose regimens of LPV/r and potential DDI risks under different drug combination scenarios. RESULTS: (AUClast) of lopinavir in co-infected pregnancy was first reported to be 34.1 and 31.0 mg/L/h for the 2nd and 3rd trimesters. The PBPK-simulated PK parameters were within 0.75 to ~ 1.16-fold of the observations at different stages of pregnancy. The m-f PBPK model-simulated umbilical vein:maternal plasma (UV:MP) ratio of lopinavir was around 0.16 at late trimester, which is consistent with the PopPK model-simulated individual value of 0.116. Simulated results indicated that a standard dose of LPV/r (400/100 mg Q12 h) might not target the effective therapeutic concentration. Model-simulated DDI results suggested that lopinavir increased dose or shortened dosing interval when co-administered with rifampicin in HIV/HBV co-infected pregnancy. CONCLUSIONS: This work successfully applied model-informed approaches to quantitatively assess lopinavir m-f PK and also provided a novel strategy for DDI risk evaluation and dosing optimization for other P-gp substrates in HIV/HBV co-infected pregnant women.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Song L, Guo X, Yang W, et al. Maternal-Fetal Physiologically Based Population Pharmacokinetics Model Development of Lopinavir/Ritonavir in HIV/HBV Co-infected Pregnant Women to Quantitatively Describe the Gestational PK Characteristics and Predict the Potential Disease-Drug-Drug Interaction (DDDI). Clin Pharmacokinet. 2025. PMID: 40323543. doi:10.1007/s40262-025-01493-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。